RSS

chronic obstructive pulmonary disease (COPD)

Shabbir Mostafa, global key account director for Recipharm Inhalation Solutions, looks at the techniques to reduce time to market during inhalation drug development and manufacturing. Read more

Opinion

Chrissy Bell, global business leader, 3M Drug Delivery Systems, looks at what the digital revolution is doing for design and commercialisation in drug delivery. Read more

News

Pharmaceutical company Orion will work together with digital therapeutics company Propeller Health on a connected drug delivery project. Read more

News

Dr David Lewis, director of Aerosol Research Chiesi discusses the environmental concerns that come with pressurised metered dose inhalers (pMDIs). Read more

Opinion

As a new era of digital drug delivery is making headway, Dr Steven Wick, vice president, Product Development & Commercialisation, 3M Drug Delivery Systems, gives us his thoughts on this digital future. Read more

Opinion

Diagnostics company, Owlstone Medical, has signed a service agreement with global biopharmaceutical company, AstraZeneca, to explore how breath can be used to identify novel biomarkers for personalised medicine applications. Read more

News

A pilot study, performed at the University of Portsmouth, has shown that a drug commonly used to thin blood, heparin, may offer a significant improvement in symptoms of chronic obstructive pulmonary disease (COPD). Read more

News

Diagnostics company, Owlstone Medical, has announced that GlaxoSmithKline (GSK) will incorporate its Breath Biopsy platform into the clinical development programme of danirixin — a novel GSK pipeline drug candidate for respiratory disease. Read more

Technology

GlaxoSmithKline (GSK) has announced that its once-daily single inhaler triple therapy, Trelegy Ellipta, for the treatment of chronic obstructive pulmonary disease (COPD) has been granted marketing authorisation by the European Commission. Read more

Technology

Clinical stage biopharmaceutical company, Pulmatrix, has received two key patents from the US Patent and Trademark Office for its inhaled drug delivery platform and its most advanced drug candidate for chronic obstructive pulmonary disease (COPD) Read more

Technology

Digital solution provider for respiratory medicine, Propeller Health, is expanding its digital health collaboration with GlaxoSmithKline (GSK) for the improvement of asthma and chronic obstructive pulmonary disease (COPD) management. Read more

News

‘Advanced simplicity’ will drive growth for inhalers in emerging markets, Peter Schmelzer, CEO of H&T Presspart tells us more. Read more

Opinion

A study published in the European Respiratory Journal, has revealed the high mortality rate and financial burden of non-tuberculosis mycobacterium pulmonary disease (NTM-PD) on patients is almost four times that of a matched group. Read more

News

GSK has sponsored the world’s first digitally enhanced randomised controlled trial (RCT) that looks at the effects of Relvar Ellipta on patients with chronic obstructive pulmonary disease (COPD) Read more

News

Aptar Pharma will unveil its Prohaler — the smart DPI for optimal patient compliance. Read more

News

New chemistry strengthens Ario Pharma’s existing TRPA1 asthma programme and reduces time to selection of new drug candidates. Read more

The Domainex compound showed more than twice the effect of the comparator drugs in reducing the cigarette smoke-induced influx of inflammatory cells, particularly neutrophils, into the lung. Read more

Call me: Me&MyCOPD mHealth uses interactive mobile phone and internet-based health tools to improve condition management for patients suffering from COPD. Read more

News

Quotient Clinical has entered a collaboration with Pulmatrix Inc., a biotech company based in Massachusetts, US, to support the development of PUR0200, a new bronchodilator therapy for the treatment of chronic obstructive pulmonary disease and the... Read more

Technology